Agree, LooseLips. So-called "smart money" is really dumb, herd-following sheep. This is a similar situation to AVXL -- now I don't have any idea whether AVXL's drug is going to end up being a genuine treatment for Alzheimer's or just another dead end (although very preliminary results look promising) -- but Big Pharma has wasted billions of dollars on research down a pathway that HASN'T WORKED. So what do they do? They spend billions more following the same failed pathway (see AXON -- billion dollar market cap, for one failed drug that they're going to try again). Yet little AVXL can't get anyone to listen when they say, hey listen, the usual type of drug hasn't worked, we have this other theory, and it seems like we might be right.

Same thing with Kevetrin. It's new, so people are saying "Show me." Fortunately, soon we WILL show them.